Cart
sales@molnova.com
Trastuzumab deruxtecan
CAS No. 1826843-81-5
Trastuzumab deruxtecan( —— )
Catalog No. M34869 CAS No. 1826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1015 | In Stock |
|
| 10MG | 1346 | In Stock |
|
| 25MG | 2017 | In Stock |
|
| 50MG | 2644 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTrastuzumab deruxtecan
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd).
-
DescriptionTrastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibody-Drug Conjugates (ADCs)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1826843-81-5
-
Formula WeightApproximately 45.42 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:? H2O : 10 mg/mL
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Evofolin C
Evofolin C and its acetate show strong antifungal and antibacterial activity. Evofolin C exhibits potent inhibition against N-formylmethionylleucylphenylalanine-induced superoxide production with IC(50) values less than 12 microM.
-
Nogo-66 (1-40)
Peptide fragment corresponding to residues 1 - 40 of Nogo-66, the domain of the myelin protein Nogo that inhibits axonal outgrowth. Acts as a competitive antagonist at the Nogo-66 receptor (NgR); blocks Nogo-66- and CNS myelin-induced inhibition of axonal growth, but does not reduce myelin-associated glycoprotein (MAG) inhibition of neurite outgrowth in vitro. Promotes regeneration of hemisected spinal axons and locomotor recovery following spinal injury in vivo.
-
Schisanhenol
Schisanhenol has antioxidative effect on human LDL oxidation, may be through scavenging free radicals. Schisanhenol has anti-apoptosis effect on BACSs, may be related to its inhibition of ROS generation.
